All News

ACR20 Podcast

ACR20 - Day 4.1, 4.2 & 4.3

d Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.

Read Article
ACR20 Podcast

ACR20 - Day 3.3 & 3.4 Podcasts

d Jack Cush, MD

Check out our many podcasts from the ACR 2020 meeting - listen in for faculty reports and overviews. You can also find the RheumNow podcast on Apple Podcast, Apple Car Play, Android Auto or where ever you prefer to listen.



Listen here:

Read Article
Accdg to this study, no association was found between IFN levels and cognitive function in SLE pts (even after considering factors like SLE dse duration) Interesting! @RheumNow #ACR20 abs1788 @ZahiTouma https://t.co/F4j8H1CWJ9
sheila RHEUMarampa ( View Tweet)
Since MTX doesn’t work in cardiac prevention in non inflammatory pop’n (CIRT trial) should we use MTX in knee OA with inflammation? RCT n=344 w primary knee OA w swelling & pain. Rx MTX v glucosamine POSITIVE results #ACR20 abstr#1648 @RheumNow @CRASCRRheum #ACRbest https://t.co/7VptCPxKU8
Janet Pope Janetbirdope ( View Tweet)
ACRmtg.jpg (keep)

ACR20 Best Abstracts - Day 3

d Jack Cush, MD

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 3 (#ACRbest).

Read Article
meeting.photo_.jpg

ACR20 - Day 2 Report

d Jack Cush, MD

Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:

Read Article
Dr. M. “Peggy” Crow’s #StateofArt lecture at #ACR20 reminds us that HCQ is the foundation of tx, to keep prednisone goal < 7.5mg/d, and that BEL works best in early dz (< 2 yrs) Summary slide provided. https://t.co/3LbWqwwOsr
Dr. Rachel Tate uptoTate ( View Tweet)
Both fat mass and fat free mass have an impact on the response to bDMARDs after 6 months of treatment in AS pts. No tx response changes w/ skeletal muscle mass, visceral fat as well as water components. #ABS1376 #ACR20 @RheumNow https://t.co/oIdE8qvJPp https://t.co/wlXFf8esey

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
Richard Conway RichardPAConway ( View Tweet)
ACR20 Podcast

ACR20 Day 2.3 Podcast

d Jack Cush, MD

Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.



Click here to listen.


Read Article
ACR20 Podcast

ACR20 Day 3.1 Podcast

d Jack Cush, MD

Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.



Click here to listen.


Read Article
ACR20 Podcast

ACR20 Day 3.2 Podcast

d Jack Cush, MD

Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.



Click here to listen.



Content covered includes:

Read Article
ACR Best

ACR20 Best Abstracts - Day 2

d Jack Cush, MD

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article
doctor.coat_.jpg

Outcomes Switching to Monotherapy: SEAM-RA Trial

d Eric Dein, MD

Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety. 

Read Article

Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest

Dr. Antoni Chan synovialjoints ( View Tweet)

Racial disparity in SSc-ILD pts treated with MMF? 1️⃣Early initiation of MMF significantly slowed ⬇️ of FVC% 2️⃣No difference in MMF efficacy between African-Americans and non-AA 3️⃣AA had baseline lower FVC% @RheumNow #ACR20 Abs0929 https://t.co/rtsbe7OCvA
Robert B Chao, MD doctorRBC ( View Tweet)
Editors Pick for #ACR20—Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial https://t.co/cunDxVl5XG https://t.co/OGItXCuWDI

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)
HCQ might decrease risk for NAFLD! Restrospective study of 5600 pts noted patients on HCQ (despite having more metabolic syndrome, HTN, DM) had 24% less incidence of NAFLD compared to pts not on HCQ Abstr#0177 #ACR20 @rheumnow https://t.co/ZoK2aC0ZQR

Links:

k dao KDAO2011 ( View Tweet)

Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confounding, diff subsets get #hydroxycholoroquine due to inflammatory arthritis etc. Maybe a big pragmatic RCT is warranted as PAH is lethal @RheumNow @CRASCRRheum #ACR20 abstr#925 https://t.co/Al81sMGgxI

Links:

Janet Pope Janetbirdope ( View Tweet)

Never forget how far we have come in rheumatology therapeutics, in a very short period of time. Some of the original slides that Tiny Maini and Marc Feldmann used. @r_burmester giving the Phillip Hench Lecture #ACR20 @RheumNow https://t.co/YI32BX2iw8
David Liew drdavidliew ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.